Caprock Group’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $13.6M | Buy |
62,485
+852
| +1% | +$189K | 0.33% | 50 |
|
|
2025
Q4 | $14.1M | Buy |
61,633
+3,201
| +5% | +$729K | 0.3% | 57 |
|
|
2025
Q3 | $12.3M | Buy |
+58,432
| New | +$11.9M | 0.3% | 53 |
|
|
2025
Q1 | $10.6M | Buy |
50,597
+7,776
| +18% | +$1.51M | 0.32% | 59 |
|
|
2024
Q4 | $7.61M | Buy |
42,821
+1,624
| +4% | +$299K | 0.25% | 66 |
|
|
2024
Q3 | $8.14M | Buy |
41,197
+3,747
| +10% | +$699K | 0.3% | 58 |
|
|
2024
Q2 | $6.42M | Buy |
37,450
+15,382
| +70% | +$2.55M | 0.26% | 61 |
|
|
2024
Q1 | $4.02M | Buy |
22,068
+2,498
| +13% | +$431K | 0.23% | 64 |
|
|
2023
Q4 | $3.03M | Buy |
19,570
+3,143
| +19% | +$458K | 0.19% | 76 |
|
|
2023
Q3 | $2.45M | Buy |
16,427
+287
| +2% | +$42.1K | 0.19% | 78 |
|
|
2023
Q2 | $2.17M | Sell |
16,140
-2,232
| -12% | -$327K | 0.16% | 99 |
|
|
2023
Q1 | $2.93M | Buy |
18,372
+2,265
| +14% | +$346K | 0.23% | 71 |
|
|
2022
Q4 | $2.6M | Sell |
16,107
-2,179
| -12% | -$334K | 0.24% | 64 |
|
|
2022
Q3 | $2.45M | Sell |
18,286
-728
| -4% | -$104K | 0.24% | 62 |
|
|
2022
Q2 | $2.91M | Buy |
19,014
+672
| +4% | +$103K | 0.29% | 53 |
|
|
2022
Q1 | $2.97M | Sell |
18,342
-1,227
| -6% | -$178K | 0.28% | 60 |
|
|
2021
Q4 | $2.65M | Sell |
19,569
-3,315
| -14% | -$392K | 0.22% | 67 |
|
|
2021
Q3 | $2.47M | Buy |
22,884
+2,953
| +15% | +$337K | 0.22% | 70 |
|
|
2021
Q2 | $2.25M | Sell |
19,931
-2,420
| -11% | -$273K | 0.2% | 79 |
|
|
2021
Q1 | $2.42M | Sell |
22,351
-6,582
| -23% | -$704K | 0.26% | 64 |
|
|
2020
Q4 | $3.1M | Sell |
28,933
-2,161
| -7% | -$208K | 0.35% | 45 |
|
|
2020
Q3 | $2.72M | Sell |
31,094
-2,231
| -7% | -$210K | 0.37% | 46 |
|
|
2020
Q2 | $3.27M | Buy |
33,325
+9,131
| +38% | +$804K | 0.49% | 37 |
|
|
2020
Q1 | $1.84M | Buy |
24,194
+3,561
| +17% | +$303K | 0.35% | 56 |
|
|
2019
Q4 | $1.83M | Buy |
20,633
+876
| +4% | +$72.7K | 0.33% | 55 |
|
|
2019
Q3 | $1.5M | Buy |
19,757
+6,132
| +45% | +$420K | 0.29% | 62 |
|
|
2019
Q2 | $991K | Sell |
13,625
-429
| -3% | -$33.7K | 0.19% | 96 |
|
|
2019
Q1 | $1.13M | Buy |
14,054
+1,379
| +11% | +$113K | 0.22% | 91 |
|
|
2018
Q4 | $1.17M | Buy |
12,675
+904
| +8% | +$79.5K | 0.27% | 75 |
|
|
2018
Q3 | $1.11M | Sell |
11,771
-420
| -3% | -$39.8K | 0.23% | 86 |
|
|
2018
Q2 | $1.13M | Sell |
12,191
-4,288
| -26% | -$419K | 0.24% | 80 |
|
|
2018
Q1 | $1.56M | Sell |
16,479
-1,491
| -8% | -$164K | 0.33% | 55 |
|
|
2017
Q4 | $1.82M | Sell |
17,970
-2,002
| -10% | -$189K | 0.35% | 54 |
|
|
2017
Q3 | $1.77M | Sell |
19,972
-1,916
| -9% | -$146K | 0.37% | 48 |
|
|
2017
Q2 | $1.59M | Buy |
21,888
+3,085
| +16% | +$207K | 0.35% | 52 |
|
|
2017
Q1 | $1.23M | Sell |
18,803
-4,287
| -19% | -$270K | 0.29% | 63 |
|
|
2016
Q4 | $1.45M | Sell |
23,090
-11,866
| -34% | -$724K | 0.36% | 55 |
|
|
2016
Q3 | $2.21M | Buy |
34,956
+320
| +0.9% | +$20.7K | 0.5% | 38 |
|
|
2016
Q2 | $2.14M | Sell |
34,636
-1,800
| -5% | -$110K | 0.52% | 43 |
|
|
2016
Q1 | $2.08M | Buy |
+36,436
| New | +$2.03M | 0.49% | 41 |
|
Other funds holding ABBV
VCM
VPM
Caprock Group's ABBV Position: Q1 2026 in Review
Caprock Group increased its AbbVie (ABBV) stake by 1.4% in Q1 2026, buying an estimated $189K and bringing the position to 62,485 shares worth $13.6M. The position accounts for 0.33% of the portfolio, ranked #50.
Caprock Group first reported a position in ABBV in Q1 2016 and has held it in 40 quarters since. The position peaked at $14.1M in Q4 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Caprock Group held 62,485 shares of AbbVie worth $13.6M as of Q1 2026.
- Caprock Group bought 852 AbbVie shares in Q1 2026, an estimated $189K.
- AbbVie made up 0.33% of Caprock Group's portfolio in Q1 2026, its #50 holding.
- Caprock Group first reported a position in AbbVie in Q1 2016 and has held it in 40 quarters since.
- Caprock Group's AbbVie position peaked at $14.1M in Q4 2025.
- 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Caprock Group's 13F filing for Q1 2026, filed 11 May 2026.